News

A Micropeptide that Inhibits Vascular Calcification via PKM2 Degradation

The vascular system is prone to calcification with advancing age. Cells in the vasculature inappropriately take on the features and behavior of the osteoblast cells responsible for building bone extracellular matrix. These errant vascular cells deposit calcium phosphate structures into vascular tissue, stiffening it. Calcification proceeds in parallel with atherosclerosis, the thickening of artery walls and generation of fatty plaques that obstruct vessels and ultimately rupture to cause a heart attack or stroke, but is an independent process that would cause dysfunction and mortality even if the causative mechanisms of atherosclerosis were eliminated. Stiffening of vascular walls, however it occurs, whether by this process, other forms of damage and change in the extracellular matrix, or loss of responsiveness to cues for contraction and dilation in […]

Laura Minquini on the Quest for Female Longevity

Laura Minquini is not a scientist, but that hasn’t stopped her from joining the front lines of the war on aging: specifically, female reproductive […]

Beyond Alzheimer’s: Quantum AI hunts new uses for XPro

INmune Bio is pairing a quantum machine with AI to find diseases beyond Alzheimer’s that its drug candidate might help. Drug developers usually pick a disease and go looking for a molecule to treat it. INmune Bio has flipped that around. It already holds a molecule, an investigational Alzheimer’s treatment called XPro (XPro1595), and it […] The post Beyond Alzheimer’s: Quantum AI hunts new uses for XPro appeared first on Longevity.Technology.

Alaunos buys Velaris, raises $350m for lung drugs

The Florida biotech takes on a pulmonary hypertension pipeline backed by Fairmount, with cash it says should last into 2029. Alaunos Therapeutics, based in Fort Lauderdale, has an obesity program at the center of how it describes itself. That program is ALN1003, an oral small molecule the company calls a non-hormonal, non-incretin approach. On 13 […] The post Alaunos buys Velaris, raises $350m for lung drugs appeared first on Longevity.Technology.

Immorta Bio’s nine-amino-acid peptide aims at zombie cells

Immorta Bio says its AI-designed SenoMune-0257 prompts T cells to clear senescent cells, and plans first human evaluation before year-end. The molecule at the center of Immorta Bio’s latest announcement is just nine amino acids long, which is tiny by drug standards. On 12 October, the Miami company said it has completed planned preclinical studies […] The post Immorta Bio’s nine-amino-acid peptide aims at zombie cells appeared first on Longevity.Technology.

Big Pharma, clocks and clinics converge at 7th TimePie Forum

TimePie’s Hebe Chen spotlights key developments from Shanghai, from therapeutic targets to China’s expanding clinical longevity footprint. A biological clock that measures the pace of aging, a drug being tested for age-related conditions, a biotech company developing new therapies, and a clinic offering longevity-focused care. These seemingly different efforts came together at the 7th TimePie […] The post Big Pharma, clocks and clinics converge at 7th TimePie Forum appeared first on Longevity.Technology.

L-Nutra Health launches metabolic programme to UK clinics

L-Nutra Health has launched a clinician-led metabolic health programme in the United Kingdom, making it available to clinics and medical practices for the first time. The programme is built on more than 25 years of research led by Dr Valter Longo and centres on the Fasting Mimicking Diet, which the company claims is a patented, […] The post L-Nutra Health launches metabolic programme to UK clinics appeared first on Longevity.Technology.

Mitochondrien: Wenn die Kraftwerke der Zellen stottern

Eine neue Theorie verbindet zahlreiche Volkskrankheiten über den Energiestoffwechsel.

NRG Therapeutics launches brain-tracking study for new neurodegenerative drug

NRG Therapeutics has started a PET imaging biodistribution trial (NRG5051-102) of its lead clinical asset NRG5051. The company says it has successfully radiolabelled NRG5051 and initiated PET scans in healthy volunteer participants in London to demonstrate central nervous system penetration and to inform dose selection for future patient trials. The study is designed to determine […] The post NRG Therapeutics launches brain-tracking study for new neurodegenerative drug appeared first on Longevity.Technology.

Muna Therapeutics’ Alzheimer’s drug MNA-001 passes early safety trial

Muna Therapeutics announced positive Phase 1 results for MNA-001, an oral small-molecule modulator of TREM2. The randomized, double-blind, placebo-controlled study assessed single- and multiple-ascending doses in younger volunteers, with an additional elderly cohort. There were no serious adverse events or discontinuations for adverse events, and most adverse events were mild. The company reports MNA-001 achieved […] The post Muna Therapeutics’ Alzheimer’s drug MNA-001 passes early safety trial appeared first on Longevity.Technology.

FDA clears NeuroXT’s AI software to assess Alzheimer’s progression risk

NeuroXT Inc. has received 510(k) clearance from the U.S. Food and Drug Administration for NEXT-Cue, an AI-based software-as-a-medical-device classified as Class II. NEXT-Cue integrates brain MRI images, demographic information, and cognitive assessment data to provide supplementary information to help clinicians assess patients with mild cognitive impairment for progression to Alzheimer’s dementia within five years. The […] The post FDA clears NeuroXT’s AI software to assess Alzheimer’s progression risk appeared first on Longevity.Technology.

Immunis wins grand prize for novel anti-aging stem cell therapy

Immunis has been awarded the Grand Prize in the National Academy of Medicine’s Healthy Longevity Global Competition for IMM01-STEM, an investigational multi-active biologic the company claims can address interconnected biological processes underlying age-related muscle and metabolic decline. The 2026 Grand Prize was open exclusively to prior Healthy Longevity Catalyst Award recipients; from 2020 to 2025 […] The post Immunis wins grand prize for novel anti-aging stem cell therapy appeared first on Longevity.Technology.

Cognition Therapeutics gets FDA alignment for Phase 3 Zervimesine trial

Cognition Therapeutics announced alignment with the U.S. Food and Drug Administration on key elements of a planned pivotal Phase 3 registrational study of Zervimesine (CT1812) in dementia with Lewy bodies. The planned study is expected to enroll participants with mild-to-moderate DLB who will be randomized to receive 100 mg once-daily oral Zervimesine or placebo for […] The post Cognition Therapeutics gets FDA alignment for Phase 3 Zervimesine trial appeared first on Longevity.Technology.

Fractyl shifts focus to Revita weight-maintenance procedure following successful trial

Fractyl is concentrating financial and operational resources on Revita after positive six-month topline results from the REMAIN-1 pivotal cohort, which met its prespecified six-month co-primary endpoint with high statistical significance (p=0.0023). The company claims Revita could become the first durable procedural therapy for post-GLP-1 weight maintenance. The company plans an FDA de novo submission in […] The post Fractyl shifts focus to Revita weight-maintenance procedure following successful trial appeared first on Longevity.Technology.

Mind the gap: pregnancy, recovery and the aging clock

A new review argues postpartum recovery may shape lifelong aging; a fandom health standard asks who helps mothers get there. Pregnancy ages a woman – measurably, if not necessarily permanently. The more interesting question, according to a new review in Trends in Endocrinology & Metabolism, is what happens afterwards. The authors, Stephen Albright and Jesse […] The post Mind the gap: pregnancy, recovery and the aging clock appeared first on Longevity.Technology.

Amylin drug cuts weight up to 9.2% in diabetes trial

Zealand Pharma’s petrelintide delivered up to 9.2% weight loss over 28 weeks in people with obesity and type 2 diabetes, with few dropouts. Here is the figure that jumped out first. Just 1.9% of people taking petrelintide in a new Phase 2 trial stopped because of stomach-related side effects. In the placebo group, it was […] The post Amylin drug cuts weight up to 9.2% in diabetes trial appeared first on Longevity.Technology.

PLA2G2F is Protective of Memory Function in the Aging Brain

Researchers here identify the gene PLA2G2F as a regulator of compensatory responses to some of the damage and dysfunction of aging. The researchers were primarily investigating a population of neurons found in the hippocampus, involved in memory function, but find that the gene is relevant in supporting cells of the brain also, such as microglia. Expression of PLA2G2F increases with age, and artificially increasing expression over natural levels produces greater protection. PLA2G2F appears to be involved in maintenance of normal lipid metabolism. Evidence suggests that dysfunctions in lipid metabolism occur in the aging brain, and cause harm via provoking greater inflammatory behavior in a number of supporting cell populations. Cognitive reserve theory posits that compensatory mechanisms during aging stave off cognitive decline and lower risk […]

The APOEε4 Variant Interferes in Myelination in the Aging Brain

Of the common variants of the APOE gene, APOEε4 presents the greatest risk of Alzheimer's disease. APOE is involved in lipid metabolism, and APOEε4 is associated with lipid-related contributions to inflammation in microglia, suggesting a primarily inflammatory mechanism for the increased risk of neurodegeneration. Here, researchers find that APOEε4 also interferes in the ability of oligodendrocyte cells to maintain the myelin structures that sheath the axons that connect neurons into neural networks, again via lipid-related mechanisms. This myelin sheathing is required for effective communication between neurons. Myelin maintenance does falter to some degree in normal aging, and the consequent loss of myelin is thought to contribute to dysfunction in the aging brain. It is reasonable to hypothesize that greater myelin loss driven by APOEε4 is […]

Type 2 immunity as a counter-regulatory axis in aging

An AI-driven model for risk stratification and prototype intervention mapping in motoric cognitive risk syndrome and subjective cognitive decline

As Alzheimer's disease and other dementias continue their global rise, there is a compelling need for early identification of pre-clinical cognitive decline. Motoric Cognitive Risk Syndrome and Subjective Cognitive Decline represent crucial transition phases to facilitate targeted intervention, and existing unimodal approaches are neither sensitive nor sufficiently multimodal for appropriate risk classification and individualized intervention mapping (prototype). This study introduces a hybrid multimodal CNN fusion framework based on an improved version of light spectrum optimizer as metaheuristic optimizer to address this challenge. The framework fuses multiple modality-specific information through parallel three-dimensional convolutional neural network branches (MRI and PET) and encoders of motor, cognitive, and biomarker information followed by a combination of intermediate and late f

Increased LINE-1 expression is associated with neuronal gene network downregulation in the aged mouse prefrontal cortex

BackgroundAging is associated with epigenetic alterations, neuroinflammation, and progressive decline of neuronal function. Derepression of the retrotransposon LINE-1 (L1) has been implicated in aging and age-related diseases. However, the regional expression of L1 and its relationships with DNA methylation, genomic L1 copy number, and aging-related transcriptional changes in the normal aging brain remain incompletely understood.MethodsWe examined L1 expression in the prefrontal cortex (PFC), hippocampus, and nucleus accumbens of young (17-week-old, n = 10) and aged (101-week-old, n = 7) male C57BL/6J mice. L1 expression, DNA methylation, and genomic copy number were quantified by RT-qPCR, pyrosequencing, and genomic qPCR, respectively. Transcriptomic alterations in the PFC were analyzed by RNA-seq, followed by weighted gene co-expression network analysis (WGCNA).ResultsL1 expression was

Editorial: The role of neurotransmitters: from normal aging to age-related diseases, volume II

Systems biology prioritizes drug candidates for an interferonresponse-high monocyte state in idiopathic normal pressure hydrocephalus

BackgroundIdiopathic normal pressure hydrocephalus (iNPH) is an age-associated neurological disorder characterized by gait disturbance, cognitive impairment, and urinary dysfunction. Although cerebrospinal fluid dynamics are central to its pathophysiology, the contribution of peripheral immune alterations remains poorly understood. We characterized an interferon-response-high monocyte state observed in iNPH and evaluated computational compound prioritization.MethodsWe used a fixed set of marker criteria to characterize the IFN-response-high monocyte state. We then compared monocyte clusters 5 and 0 and used 150 upregulated and 150 downregulated genes to screen compounds in LINCS. We tested whether candidate rankings changed with different state definitions, comparison groups, gene-list sizes, clustering settings, and inclusion of all patients. We also repeated the queries after excluding

Editorial: Decoding the gut-brain axis: implications for neurodegenerative disease therapies

Reprogramming the gut–brain axis in neurodegeneration: comparative microbiome, metabolite, immunometabolic, polyphenol, probiotic, and epigenetic mechanisms in Alzheimer’s and Parkinson’s diseases

The gut–brain axis has emerged as a central mechanistic framework linking dietary bioactives, microbial ecology, and neurodegenerative disease progression. Similar microbiome-related mechanisms have also been implicated in colorectal cancer, suggesting potential shared links between microbial dysbiosis, inflammation, and disease progression. This study synthesizes preclinical evidence examining how polyphenols, polyphenol-derived compounds, and advanced delivery systems, including nanoparticles and synbiotics, modulate Alzheimer’s disease (AD) and Parkinson’s disease (PD) through microbiome-dependent mechanisms. Evidence from transgenic mice, toxin-induced rodent models, and Drosophila systems was compared across microbiome alterations, microbial metabolites, signaling pathways, epigenetic regulation, and functional outcomes. Across AD and PD models, dietary bioactives consistently promo

Microbial metabolites as modulators of gut–brain communication in neurodegeneration: from intestinal sensing to disease initiation and progression

How heterogeneous gut metabolite alterations relate to Parkinson’s disease (PD) and Alzheimer’s disease (AD) remains unresolved. We propose a framework in which intestinal sensing of indole derivatives, short-chain fatty acids and bile acids links microbial function to barrier regulation and gut–brain communication. Integration denotes tissue-level convergence of aryl hydrocarbon receptor (AhR), pregnane X receptor (PXR) and metabolite-responsive G-protein-coupled receptor responses across epithelial and neighbouring immune cells, rather than an established same-cell receptor complex. Tryptophan metabolism provides an analytical focus connecting microbial indole production with host kynurenine and serotonin pathways; metabolite concentrations alone do not establish pathway flux or receptor activity. We hypothesise that suppressed indole-associated epithelial signalling, barrier hyperperm

How Some Neuronal Cilia May Affect the Whole Body

A team of researchers has written a paper with a surprising finding: that many of the benefits of caloric restriction and increased NAD+ may be due to their effects on the cilia of hypothalamic neurons. Neuronal cilia have a […]

Topical Urolithin A to Improve Aged Skin Function

Mitochondria are the power plants of the cell, creating the chemical energy store molecule adenosine triphosphate used to power cellular processes. Mitochondrial function declines with age, and the research community is engaged in a variety of approaches that might at least modestly reduce this loss. The supplement urolithin A is known to improve mitochondrial function, though, and as is the case for other approaches, how exactly urolithin A accomplishes this outcome is not fully understood. Most of the ways to modestly improve mitochondrial function, ranging from exercise and calorie restriction through to NAD+ upregulation via vitamin B3 derivatives and MitoQ, may primarily function through improvements to autophagy targeted at mitochondria, improving overall mitochondrial function via improved clearance of damaged and dysfunctional mitochondria. This is by […]

Giving birth again too soon after having a baby could lead to quicker biological aging

The study of biological aging, how our cells, tissues and organs change over time, independent of how many years have passed, is a growing area of research that aims to help scientists understand the root causes of chronic illnesses and find ways to enhance longevity. A review article published in Trends in Endocrinology & Metabolism discusses the connections between pregnancy and biological aging.

Niagen expands at-home injection kit with new liquid format

Niagen Bioscience’s new Niagen Plus vial comes pre-filled and needs no mixing. It is available via a telehealth platform from 22 October. The pitch for Niagen Bioscience’s latest product starts with what has been taken out of the process. Older injectable formats need mixing or reconstitution before use. The new Niagen Plus vial arrives as […] The post Niagen expands at-home injection kit with new liquid format appeared first on Longevity.Technology.

Millions take fish oil for brain health. A two-year study found no benefit

A surprising two-year clinical trial found that fish oil supplements successfully delivered omega-3s to the brain but failed to improve memory or protect against Alzheimer's-related brain shrinkage. Researchers suspect that getting these nutrients through a healthy diet may offer benefits that supplements alone cannot provide.

Zealand taps Generate’s AI for obesity proteins in nearly $1.2b deal

Zealand Pharma and Generate Biomedicines will design multispecific proteins for metabolic disease, in a deal with nearly $1.2b in milestones. Zealand Pharma has been a peptide company for more than 25 years, and now the Copenhagen outfit is asking an AI specialist to help it branch into proteins. The announcement came on 13 October. Zealand […] The post Zealand taps Generate’s AI for obesity proteins in nearly $1.2b deal appeared first on Longevity.Technology.

Lewy body drug candidate gets patent cover to 2045

Cognition Therapeutics wins a US patent on a new crystal form of zervimesine and has an FDA meeting on its Lewy body trial lined up. Cognition Therapeutics announced that its lead drug candidate, zervimesine (CT1812), now has patent protection running to 2045. The US Patent and Trademark Office granted a patent on a novel crystalline […] The post Lewy body drug candidate gets patent cover to 2045 appeared first on Longevity.Technology.

NeuroXT earns FDA clearance for AI brain scan analyzer for Alzheimer’s

NeuroXT Inc announced that NEXT-Cue, its AI-based Software as a Medical Device supporting prognostic assessment in patients with mild cognitive impairment, has received 510(k) clearance from the U.S. Food and Drug Administration as a Class II medical device. NEXT-Cue integrates brain MRI images, demographic data and cognitive assessment results to provide supplementary information intended to […] The post NeuroXT earns FDA clearance for AI brain scan analyzer for Alzheimer’s appeared first on Longevity.Technology.

Fountain Life named Longevity Clinic of the Year

Fountain Life has been named Longevity Clinic of the Year 2026 by the Roundtable of Longevity Clinics, marking its second consecutive year receiving the award. The award was presented in conjunction with the Roundtable at the Buck Institute for Research on Aging in Novato, California. Its longitudinal dataset includes more than 15 billion clinical data […] The post Fountain Life named Longevity Clinic of the Year appeared first on Longevity.Technology.

Loss of Oocyte Ribosomal Function as a Contribution to Female Reproductive Aging

Why, mechanistically, is female reproductive aging so accelerated in relation to the rest of the aging process? Researchers here point to a role for a progressive loss of ribosomes in oocytes. Cells contain many ribosomes, vital components of the cell where messenger RNA is translated into protein, and usually synthesize more as needed. Oocytes do not tend to synthesize new ribosomes, however, one of many differences in behavior intended to retain a much higher standard of cell quality during the reproductive lifespan. Female germline cells are among the most protected of all cell types, and have to be in order to maintain a sufficiently low level of reproductive failure for evolutionary success. Here, it is suggested that this ribosomal approach to increased cell quality produces […]

Thoughts on When Aging Clocks Can Be Trusted

Aging clocks can be produced from large databases of near any form of biological data that changes with age via the use of machine learning techniques that identify weighted combinations of measures that correlate strongly with chronological age, remaining life expectancy, mortality risk, and so forth. The true goal of developing clock technology is to find a way to rapidly assess the quality of any new potential therapy to slow or reverse aspects of aging, and thus greatly accelerate research and development, focusing attention on the best possible approaches. Unfortunately no clock can be trusted to perform accurately in the face of a new approach to treat aging. A clock could underestimate, overestimate, or be unaffected by biological changes that do have meaningful effects on […]

Rebalancing the body's cellular communication system could slow aging

Researchers have outlined a plan for slowing aging by targeting one of the body's most important cellular communication systems. In a new paper published in Frontiers in Science, scientists describe how novel therapies that modulate GPCR signaling could one day help delay multiple age-related diseases at once—potentially extending healthy years of life.

Eos puts new gerotherapeutic to the test in aging mice

Berlin keynote details Eos SENOLYTIX’s pre-clinical results with mitochondrial-targeted geropeptide on healthspan and lifespan. A 167-week-old mouse makes an unlikely but persuasive ambassador for geroscience, particularly when he appears to be moving around with considerably more energy than animals more than a year his junior. For Eos SENOLYTIX, the animal known as Speedy represents something […] The post Eos puts new gerotherapeutic to the test in aging mice appeared first on Longevity.Technology.

Eos SENOLYTIX invites the public to keep pace with Speedy

As its CEO takes the stage in Berlin, the company opens a window on its longest-lived treated mice – and the data behind them. Most laboratory mice live and die in obscurity. Speedy has a webpage. From today, Eos SENOLYTIX is posting a 30-second clip of the 167-week-old mouse each morning, taken from his previous […] The post Eos SENOLYTIX invites the public to keep pace with Speedy appeared first on Longevity.Technology.